{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:18:44Z","timestamp":1790014724120,"version":"4.0.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["U01FD004947"],"award-info":[{"award-number":["U01FD004947"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s11095-022-03199-w","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T22:02:41Z","timestamp":1649714561000},"page":"703-719","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Investigator Impact on Reproducibility of Drug Bioavailability in Stratum Corneum Sampling by Tape Stripping"],"prefix":"10.1007","volume":"39","author":[{"given":"Sagar","family":"Shukla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette L.","family":"Bunge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem E.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7316-969X","authenticated-orcid":false,"given":"Audra L.","family":"Stinchcomb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"key":"3199_CR1","unstructured":"United States Food and Drug Administration. Approved drug products with therapeutic equivalence evaluations (orange book). 2021. [Internet]. [cited 2021 Sep 27]. Available from:\u00a0https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/approved-drug-products-therapeutic-equivalence-evaluations-orange-book. Accessed 27 Sept 2021"},{"key":"3199_CR2","doi-asserted-by":"crossref","unstructured":"Midha KK, McKay G. Bioequivalence; its history, practice, and future. AAPS J [Internet]. 2009 Dec;11(4):664\u201370. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19806461","DOI":"10.1208\/s12248-009-9142-z"},{"key":"3199_CR3","doi-asserted-by":"crossref","unstructured":"Petersen B, Rovati S. Diclofenac epolamine (Flector) patch: evidence for topical activity. Clin Drug Investig [Internet]. 2009;29(1):1\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19067470","DOI":"10.2165\/0044011-200929010-00001"},{"key":"3199_CR4","doi-asserted-by":"crossref","unstructured":"Herkenne C, Alberti I, Naik A, Kalia YN, Mathy F-X, Pr\u00e9at V, et al. In vivo methods for the assessment of topical drug bioavailability. Pharm Res [Internet]. 2008 Jan;25(1):87\u2013103. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17985216","DOI":"10.1007\/s11095-007-9429-7"},{"key":"3199_CR5","doi-asserted-by":"crossref","unstructured":"Chang R-K, Raw A, Lionberger R, Yu L. Generic development of topical dermatologic products: formulation development, process development, and testing of topical dermatologic products. AAPS J [Internet]. 2013 Jan;15(1):41\u201352. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23054971","DOI":"10.1208\/s12248-012-9411-0"},{"key":"3199_CR6","doi-asserted-by":"crossref","unstructured":"Miranda M, Cardoso C, Vitorino C. Quality and equivalence of topical products: a critical appraisal. Eur J Pharm Sci [Internet]. 2019 Oct 15;105082. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31626969","DOI":"10.1016\/j.ejps.2019.105082"},{"key":"3199_CR7","unstructured":"United States Food and Drug Administration. Draft guidance on Lidocaine. 2018. [Internet]. [cited 2020 Feb 13]. Available from:\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/Lidocaine_draft_Topical.patch_RLD020612_RC10-18.pdf\n. Accessed 13 Feb 2020"},{"key":"3199_CR8","unstructured":"United States Food and Drug Administration. Draft guidance on acyclovir. 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/Acyclovir_topical%20cream_RLD%2021478_RV12-16.pdf. Accessed 13 Feb 2020."},{"key":"3199_CR9","unstructured":"Dandamudi S. In vitro bioequivalence data for a topical product: bioequivalence review perspective. Oral presentation at: FDA Public Workshop Topical Dermatological Generic Drug Products; October 20, 2017 [Internet]. [cited 2020 Feb 13]. Available from:\u00a0https:\/\/www.fda.gov\/media\/110389\/download. Accessed 13 Feb 2020"},{"key":"3199_CR10","unstructured":"United States Food and Drug Administration. Draft guidance on Ivermectin. 2019. [Internet]. [cited 2021 Apr 27]. Available from:\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/Ivermectin.TopicalCream1NDA206255PSGPageRVMay2019.pdf. Accessed 27 April 2021"},{"key":"3199_CR11","unstructured":"United States Food and Drug Administration. Draft guidance on Clindamycin Phosphate. 2019. [Internet]. [cited 2021 Apr 27]. Available from:\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/PSG_050615.pdf.\u00a0Accessed 27 April 2021"},{"key":"3199_CR12","doi-asserted-by":"crossref","unstructured":"Shah VP, Yacobi A, R\u0103dulescu F\u015e, Miron DS, Lane ME. A science based approach to topical drug classification system (TCS). Int J Pharm [Internet]. 2015 Aug;491(1\u20132):21\u20135. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517315005220","DOI":"10.1016\/j.ijpharm.2015.06.011"},{"key":"3199_CR13","unstructured":"Advances in Topical Bioequivalence Assessments: Characterization-Based Approaches. Oral Presentation at University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) [Internet]. [cited 2021 Apr 27]. Available from:\u00a0https:\/\/cersi.umd.edu\/sites\/cersi.umd.edu\/files\/Day.1-2SamRaneyUofM-CERSI2020_0.pdf. Accessed 27 April\u00a02021"},{"key":"3199_CR14","unstructured":"United States Food and Drug Administration. Guidance for industry: Statistical Approaches to Establishing Bioequivalence. 2001. [Internet]. [cited 2021 Sep 27]. Available from:\u00a0https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm070244.pdf. Accessed 13 Feb 2020"},{"key":"3199_CR15","doi-asserted-by":"crossref","unstructured":"N\u2019Dri-Stempfer B, Navidi WC, Guy RH, Bunge AL. Improved bioequivalence assessment of topical dermatological drug products using dermatopharmacokinetics. Pharm Res [Internet]. 2009 Feb;26(2):316\u201328. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18941872","DOI":"10.1007\/s11095-008-9742-9"},{"key":"3199_CR16","doi-asserted-by":"crossref","unstructured":"Cordery SF, Pensado A, Chiu WS, Shehab MZ, Bunge AL, Delgado-Charro MB, et al. Topical bioavailability of diclofenac from locally-acting, dermatological formulations. Int J Pharm [Internet]. 2017 Aug 30;529(1\u20132):55\u201364. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28636892","DOI":"10.1016\/j.ijpharm.2017.06.063"},{"key":"3199_CR17","doi-asserted-by":"crossref","unstructured":"Pensado A, Chiu WS, Cordery SF, Rantou E, Bunge AL, Delgado-Charro MB, et al. Stratum corneum sampling to assess bioequivalence between topical acyclovir products. Pharm Res [Internet]. 2019 Nov 14;36(12):180. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31728737","DOI":"10.1007\/s11095-019-2707-3"},{"key":"3199_CR18","doi-asserted-by":"crossref","unstructured":"Escobar-Ch\u00e1vez JJ, Merino-Sanju\u00e1n V, L\u00f3pez-Cervantes M, Urban-Morlan Z, Pi\u00f1\u00f3n-Segundo E, Quintanar-Guerrero D, et al. The tape-stripping technique as a method for drug quantification in skin. J Pharm Pharm Sci [Internet]. 2008;11(1):104\u201330. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18445368","DOI":"10.18433\/J3201Z"},{"key":"3199_CR19","unstructured":"European Medicines Agency. Draft guideline on quality and equivalence of topical products [Internet]. [cited 2021 Apr 27]. Available from:\u00a0https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-quality-equivalence-topical-products_en.pdf. Accessed 27 April 2021"},{"key":"3199_CR20","doi-asserted-by":"crossref","unstructured":"Yacobi A, Shah VP, Bashaw ED, Benfeldt E, Davit B, Ganes D, et al. Current challenges in bioequivalence, quality, and novel assessment technologies for topical products. Pharm Res [Internet]. 2014 Apr;31(4):837\u201346. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24395404","DOI":"10.1007\/s11095-013-1259-1"},{"key":"3199_CR21","doi-asserted-by":"crossref","unstructured":"Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. Clin Pharmacokinet [Internet]. 1997 Sep;33(3):184\u2013213. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9314611","DOI":"10.2165\/00003088-199733030-00003"},{"key":"3199_CR22","unstructured":"United States Food and Drug Administration. Draft guidance for industry: topical dermatological drug product NDAs and ANDAs\u2014in vivo bioavailability, bioequivalence, in vitro release, and associated studies. 1998. [Internet]. [cited 2020 Mar 6]. Available from:\u00a0https:\/\/pdfs.semanticscholar.org\/18c4\/a3a9696003e353f2cc7830560e828a89eed5.pdf?_ga=2.61590767.2143012472.1583526789-1250934800.1583526789. Accessed\u00a0 06 March 2020"},{"key":"3199_CR23","doi-asserted-by":"crossref","unstructured":"Shah VP, Flynn GL, Yacobi A, Maibach HI, Bon C, Fleischer NM, et al. Bioequivalence of topical dermatological dosage forms--methods of evaluation of bioequivalence. AAPS\/FDA Workshop on \u201cBioequivalence of Topical Dermatological Dosage Forms-- Methods of Evaluating Bioequivalence\u201d, September 4\u20136, 1996, Bethesda, Md. Skin Pharmacol Appl Skin Physiol [Internet]. 11(2):117\u201324. Available from:\u00a0http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9603663. Accessed 22 Jan 2020","DOI":"10.1159\/000029817"},{"key":"3199_CR24","unstructured":"Draft guidance for industry on topical dermatological drug product NDAs and ANDAs-in vivo bioavailability, bioequivalence, in vitro release and associated studies; withdrawal (2002). Fed Reg. 2002;67:35122\u20133.\u00a0https:\/\/www.federalregister.gov\/articles\/2002. Accessed 13 Feb 2020"},{"key":"3199_CR25","doi-asserted-by":"crossref","unstructured":"Raney SG, Franz TJ, Lehman PA, Lionberger R, Chen M-L. Pharmacokinetics-based approaches for bioequivalence evaluation of topical dermatological drug products. Clin Pharmacokinet [Internet]. 2015 Nov;54(11):1095\u2013106. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26063051","DOI":"10.1007\/s40262-015-0292-0"},{"key":"3199_CR26","doi-asserted-by":"crossref","unstructured":"N\u2019Dri-Stempfer B, Navidi WC, Guy RH, Bunge AL. Optimizing metrics for the assessment of bioequivalence between topical drug products. Pharm Res [Internet]. 2008 Jul;25(7):1621\u201330. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18449629","DOI":"10.1007\/s11095-008-9577-4"},{"key":"3199_CR27","doi-asserted-by":"crossref","unstructured":"Navidi W, Hutchinson A, N\u2019Dri-Stempfer B, Bunge A. Determining bioequivalence of topical dermatological drug products by tape-stripping. J Pharmacokinet Pharmacodyn [Internet]. 2008 Jun;35(3):337\u201348. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18465213","DOI":"10.1007\/s10928-008-9091-7"},{"key":"3199_CR28","unstructured":"Shukla S. Evaluation of skin tape stripping in healthy human volunteers as a methodology for quantifying local drug bioavailability from dermal products (Document No. 27993494) [Doctoral dissertation, University of Maryland School of Pharmacy]. ProQuest Dissertations Publishing.\u00a02020"},{"key":"3199_CR29","doi-asserted-by":"publisher","unstructured":"M. Alice Maciel Tabosa, Sarah F. Cordery, K.A. Jane White, Annette L. Bunge, Richard H. Guy, M. Begona Delgado-Charro, \u201cSkin pharmacokinetics of diclofenac and co-delivered excipients\u201d.\u00a0 Intl J Pharm. 2022;614:121469. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.121469","DOI":"10.1016\/j.ijpharm.2022.121469"},{"key":"3199_CR30","unstructured":"Lidoderm [package insert]. Chadds Ford, PA: Endo Pharmaceuticals Inc.; 2004. [Internet]. [cited 2020 Feb 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/020612s014lbl.pdf. Accessed 13 Feb 2020"},{"key":"3199_CR31","unstructured":"Lidocaine patch 5% [package insert].Morgantown, WV: Mylan Pharmaceuticals Inc.;2018. [Internet]. [cited 2020 Feb 13]. Available from:\u00a0https:\/\/dailymed.nlm.nih.gov\/dailymed\/getFile.cfm?setid=5c66f3b9-6e04-47ab-8d94-21e89ceec154&type=pdf&name=5c66f3b9-6e04-47ab-8d94-21e89ceec154. Accesed. 13 Feb 2020"},{"key":"3199_CR32","doi-asserted-by":"crossref","unstructured":"Drago S, Imboden R, Schlatter P, Buylaert M, Kr\u00e4henb\u00fchl S, Drewe J. Pharmacokinetics of transdermal etofenamate and diclofenac in healthy volunteers. Basic Clin Pharmacol Toxicol [Internet]. 2017 Nov;121(5):423\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28561421","DOI":"10.1111\/bcpt.12818"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-022-03199-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-022-03199-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-022-03199-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T14:14:15Z","timestamp":1652192055000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-022-03199-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["3199"],"URL":"https:\/\/doi.org\/10.1007\/s11095-022-03199-w","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"19 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no financial or proprietary interests in any material discussed in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest statement"}}]}}